Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2006

View Archived Issues

ViroPharma reveals health initiatives to combat C. difficile-associated disease

MediVas reports promising data from preclinical H5N1 vaccine study

MMV, Genzyme and Broad Institute expand collaboration for malaria

Phase II study of atiprimod in advanced carcinoid patients opens

New program studies AVI-5126 for use in CABG

Closing of Cell Therapeutics' agreement with Novartis

Adjuvant phytotherapy for Parkinson's disease

FDA approval for Coreg CR

First selective KAT II inhibitor targeted for procognition presented at SfN

WBI-1001 for psoriasis completes key preclinical studies

Positive findings from pilot study of alkaline phosphatase in sepsis

New trial studies Alimta in extensive-stage small cell lung cancer

Jennerex and Green Cross sign agreement for JX-594 in Korea

Inhibition of TFFs causes regression of human breast cancers in animal models

NeuroSearch reports on a novel SK channel negative modulator

Novel antiobesity compounds from Prosidion avoid sympathetic-driven complications

Mechanisms underlying the anticonvulsant activity of alpha-substituted lactams

Recent patents cover novel immunomodulators

Recent Organon and Microbia patents report new therapeutic agents for metabolic disorders

Variations in endothelin-converting enzyme-like 1 gene linked to type 2 diabetes

Mutations in neuronal UCP genes may affect risk of schizophrenia

Approval for Reyataz 300 mg single capsule formulation

Approvable letter for Gestiva

Altana receives approval for ciclesonide nasal spray

MEFV found to be a disease susceptibility gene for IBD

Desonate approved for mild to moderate atopic dermatitis

Betaseron approved for use after first event suggestive of MS

Nonapprovable letter for faropenem medoxomil

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...